Alpha Tau Medical Stock Today
| DRTS Stock | USD 2.32 0.02 0.87% |
Performance3 of 100
| Odds Of DistressLess than 30
|
Alpha Tau is selling for under 2.32 as of the 25th of November 2024; that is 0.87 percent increase since the beginning of the trading day. The stock's lowest day price was 2.3. Alpha Tau has about a 30 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Alpha Tau Medical are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 29th of February 2024 and ending today, the 25th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 8th of March 2021 | Category Healthcare | Classification Health Care |
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of solid cancer In Israel and the United States. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel. The company has 70.1 M outstanding shares of which 67.06 K shares are currently shorted by private and institutional investors with about 3.01 trading days to cover. More on Alpha Tau Medical
Moving against Alpha Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Alpha Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Thematic Idea | Medical Equipment (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Medical Equipment, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsAlpha Tau can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Alpha Tau's financial leverage. It provides some insight into what part of Alpha Tau's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Alpha Tau Medical (DRTS) is traded on NASDAQ Exchange in USA. It is located in Kiryat Hamada Street 5, Jerusalem, Israel, 9777605 and employs 121 people. Alpha Tau is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 162.64 M. Alpha Tau Medical conducts business under Biotechnology sector and is part of Health Care industry. The entity has 70.1 M outstanding shares of which 67.06 K shares are currently shorted by private and institutional investors with about 3.01 trading days to cover.
Alpha Tau Medical currently holds about 112.04 M in cash with (17.96 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.63.
Check Alpha Tau Probability Of Bankruptcy
Ownership AllocationAlpha Tau holds a total of 70.1 Million outstanding shares. Alpha Tau Medical retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Alpha Ownership Details
Alpha Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Northern Trust Corp | 2024-09-30 | 22.9 K | |
| Aptus Capital Advisors, Llc | 2024-06-30 | 21.9 K | |
| Citadel Advisors Llc | 2024-09-30 | 16.3 K | |
| Renaissance Technologies Corp | 2024-09-30 | 14.2 K | |
| Tuttle Capital Management, Llc | 2024-09-30 | 12.2 K | |
| Usadvisors Wealth Management, Llc | 2024-09-30 | 10.7 K | |
| Opal Wealth Advisors, Llc | 2024-09-30 | 10 K | |
| Steward Partners Investment Advisory, Llc | 2024-06-30 | 6 K | |
| Tower View Investment Management & Research Llc | 2024-09-30 | 5.6 K | |
| Easterly Investment Partners. | 2024-09-30 | 307.3 K | |
| Hoylecohen, Llc | 2024-06-30 | 269.1 K |
Alpha Tau Historical Income Statement
Alpha Stock Against Markets
Alpha Tau Corporate Management
| Robert MD | Chief Board | Profile | |
| Rebecca Becker | Vice legal | Profile | |
| Pr Kelson | Chief Board | Profile | |
| Yael Zeiger | Corporate Controller | Profile | |
| Raphi Levy | Chief Officer | Profile | |
| Peter Melnyk | Chief Officer | Profile | |
| Pr Keisari | Chief board | Profile |
Additional Tools for Alpha Stock Analysis
When running Alpha Tau's price analysis, check to measure Alpha Tau's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alpha Tau is operating at the current time. Most of Alpha Tau's value examination focuses on studying past and present price action to predict the probability of Alpha Tau's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alpha Tau's price. Additionally, you may evaluate how the addition of Alpha Tau to your portfolios can decrease your overall portfolio volatility.